| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
63,610,000 |
| Market
Cap: |
322.50(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.6 - $8.07 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile MeiraGTx Holdings is a clinical stage gene therapy company with six programs in clinical development and a pipeline of preclinical and research programs. Co.'s focus is on three areas of unmet medical need: ocular, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases and severe forms of xerostomia. Co.'s product candidates include: AAV-RPE65 for the treatment of retinal dystrophy associated with mutations in the RPE65 gene; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of Leber congenital amaurosis 4; as well as AAV-RDH12 for the treatment of RDH12 Mutation-Associated Retinal Dystrophy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
4,353,826 |
| Total Buy Value |
$0 |
$0 |
$0 |
$25,047,440 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Forbes Alexandria |
PRESIDENT & CEO |
• • – |
2023-01-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
48,750 |
1,103,953 |
|
- |
|
| Johnson & Johnson Development Corp Et Al |
10% Owner |
– – • |
2022-11-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,641,064 |
|
-24% |
|
| Zeldin Robert K |
CHIEF MEDICAL OFFICER |
• – – |
2022-06-03 |
4 |
B |
$7.89 |
$39,500 |
D/D |
5,000 |
5,000 |
0.01 |
2% |
|
| Wollin Robert J |
GENERAL COUNSEL AND SECRETARY |
• – – |
2022-05-25 |
4 |
B |
$7.94 |
$7,940 |
D/D |
1,000 |
1,000 |
0.01 |
12% |
|
| Forbes Alexandria |
President and CEO |
• • – |
2022-01-08 |
4 |
D |
$21.53 |
$1,109,958 |
D/D |
(51,554) |
1,109,227 |
|
- |
|
| Forbes Alexandria |
President and CEO |
• • – |
2022-01-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
97,500 |
1,160,781 |
|
- |
|
| Giroux Richard |
CFO & COO |
• – – |
2022-01-08 |
4 |
D |
$21.53 |
$853,815 |
D/D |
(39,657) |
848,661 |
|
- |
|
| Giroux Richard |
CFO & COO |
• – – |
2022-01-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
75,000 |
888,318 |
|
- |
|
| Naylor Stuart |
Chief Development Officer |
• – – |
2022-01-08 |
4 |
D |
$21.53 |
$809,528 |
D/D |
(37,600) |
444,417 |
|
- |
|
| Naylor Stuart |
Chief Development Officer |
• – – |
2022-01-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
80,000 |
482,017 |
|
- |
|
| Forbes Alexandria |
President and CEO |
• • – |
2021-11-17 |
4 |
AS |
$19.86 |
$297,900 |
D/D |
(15,000) |
1,080,781 |
|
-30% |
|
| Forbes Alexandria |
President and CEO |
• • – |
2021-11-16 |
4 |
AS |
$19.82 |
$299,572 |
D/D |
(15,000) |
1,095,781 |
|
-30% |
|
| Giroux Richard |
CFO & COO |
• – – |
2021-10-20 |
4 |
AS |
$20.93 |
$435,686 |
D/D |
(20,700) |
819,218 |
|
-34% |
|
| Giroux Richard |
CFO & COO |
• – – |
2021-10-19 |
4 |
AS |
$20.07 |
$26,091 |
D/D |
(1,300) |
839,918 |
|
-26% |
|
| Forbes Alexandria |
President and CEO |
• • – |
2021-10-18 |
4 |
AS |
$17.21 |
$520,687 |
D/D |
(30,000) |
1,110,781 |
|
-25% |
|
| Naylor Stuart |
Chief Development Officer |
• – – |
2021-10-18 |
4 |
AS |
$17.95 |
$215,400 |
D/D |
(12,000) |
402,017 |
|
-25% |
|
| Naylor Stuart |
Chief Development Officer |
• – – |
2021-07-20 |
4 |
AS |
$15.06 |
$141,413 |
D/D |
(9,390) |
414,017 |
|
23% |
|
| Naylor Stuart |
Chief Development Officer |
• – – |
2021-07-13 |
4 |
AS |
$15.04 |
$39,254 |
D/D |
(2,610) |
423,407 |
|
34% |
|
| Forbes Alexandria |
President and CEO |
• • – |
2021-06-09 |
4 |
AS |
$15.04 |
$62,461 |
D/D |
(4,153) |
1,290,781 |
|
-6% |
|
| Naylor Stuart |
Chief Development Officer |
• – – |
2021-06-08 |
4 |
AS |
$15.01 |
$75,650 |
D/D |
(5,040) |
426,017 |
|
-10% |
|
| Forbes Alexandria |
President and CEO |
• • – |
2021-06-08 |
4 |
AS |
$15.02 |
$303,104 |
D/D |
(20,180) |
1,294,934 |
|
-10% |
|
| Naylor Stuart |
Chief Development Officer |
• – – |
2021-06-07 |
4 |
AS |
$15.02 |
$15,651 |
D/D |
(1,042) |
431,057 |
|
-10% |
|
| Forbes Alexandria |
President and CEO |
• • – |
2021-06-07 |
4 |
AS |
$15.03 |
$85,175 |
D/D |
(5,667) |
1,315,114 |
|
-10% |
|
| Naylor Stuart |
Chief Development Officer |
• – – |
2021-04-30 |
4/A |
AS |
$15.01 |
$11,122 |
D/D |
(741) |
432,099 |
|
- |
|
| Naylor Stuart |
Chief Development Officer |
• – – |
2021-04-30 |
4 |
S |
$15.01 |
$11,122 |
D/D |
(741) |
432,099 |
|
19% |
|
130 Records found
|
|
Page 3 of 6 |
|
|
0.03 (0.59%) 
